Lombardi director receives international award for research achievements


Washington, DC --Richard Pestell, MD, PhD, director of Georgetown's Lombardi Comprehensive Cancer Center, accepted the Endocrine Society of Australia's highest award, the Keith Harrison Plenary Lecture and Award, on Sept. 6 at the society's annual scientific meeting in Australia. The award recognizes discoveries on breast and prostate cancer in Pestell's lab at Georgetown University. He also delivered a lecture at Curtin University of Technology on new opportunities in cancer therapy during his visit.

"Dr. Pestell richly deserves this distinguished recognition because of his important fundamental contributions to our understanding of endocrinology and cancer, as well as his farsighted leadership of Georgetown's laboratories, research programs and our Lombardi Comprehensive Cancer Center," said Stuart Bondurant, MD, interim executive vice president for health sciences at Georgetown University.

Pestell, an internationally renowned expert in oncology and endocrinology, was named Lombardi's director in September 2002. He is a highly respected researcher and clinician whose current work is focused on developing new cancer therapies that specifically target tumors and reduce the side effects that are associated with commonly used cancer treatments such as chemotherapy and radiation.

Pestell's research concentrates on identifying molecular markers of pre-malignant disease to develop preventive approaches to cancer. He has made significant contributions to the understanding of cell cycle regulation and the disturbances that can lead to the malignant transformation of cells.

Pestell has particular expertise in hormonally-responsive tumors, including breast and prostate cancer, and his work is directed toward the discovery of novel therapies for these cancers.

The author of more than 220 research papers and reviews and 130 research abstracts, Pestell has consistently published in leading journals including Cell, Science and Nature Medicine. He has an outstanding record of obtaining funding, with current funding, including five NIH RO1 grants funded by the National Institutes of Health, totaling more than $20 million.

Source: Eurekalert & others

Last reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
    Published on PsychCentral.com. All rights reserved.